

25 (new). The process according to claim 24, wherein said paroxetine methane sulfonate is crystalline.

26 (new). The process according to claim 25, wherein said crystalline paroxetine methane sulfonate was prepared by crystallizing paroxetine methane sulfonate from ethyl acetate.

27 (new). Paroxetine hydrochloride made by the process of claim 24.

28 (new). Paroxetine hydrochloride made by the process of claim 25.

29 (new). Paroxetine hydrochloride made by the process of claim 26.

REMARKS

Claims 1-23 have been cancelled and replaced with new claims 24-29 in this divisional application. Support for the new claims is believed to be self-evident. However, for the Examiner's convenience, her attention is directed to, *inter alia*, the description at page 8, line 23, and the surrounding text as well as to original claim 15. Further the Experimental and Example 1 procedures on pages 9-11 of the specification describe the formation of crystalline paroxetine methane sulfonate and in both procedures ethyl acetate is used as the solvent from which the crystals were formed. Accordingly, no new matter has been introduced into the application by the above-amendment.